Evidence map›Paper›PMID 18044074›Full record

ReviewClinical interventions in aging2007

Immunosupportive therapies in aging.

Tamas Fülöp, Anis Larbi, Katsuiku Hirokawa, Eugenio Mocchegiani, Bruno Lesourds, Stephen Castle, Anders Wikby, Claudio Franceschi, Graham Pawelec

Open access · goldAbstract readReview
In one paragraph

Review in Clinical interventions in aging, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 70 citations in OpenAlex.

  1. Review
  2. Late-onset psoriatic arthritis: data from a nationwide cross-sectional study.Therapeutic advances in musculoskeletal disease · 2025
    Article
  3. Review
  4. Review
  5. Immunomodulation in age-related disorders and nanotechnology interventions.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2023
    Review
  6. Article
  7. Article
  8. Evaluating Immune Dysregulation in Patients With COVID-19 Requires a More Accurate Definition of the CD45RA+ T-cell Phenotype.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Vaccination in the elderly.Microbial biotechnology · 2012
    Review
  15. Article
  16. Cancer surgery in the elderly.TheScientificWorldJournal · 2012
    Review
  17. A molecular mechanism for TNF-α-mediated downregulation of B cell responses.Journal of immunology (Baltimore, Md. : 1950) · 2012
    Article
  18. Review
  19. Review
  20. Immunity, ageing and cancer.Immunity & ageing : I & A · 2008
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Tamas FülöpResearch Center on Aging, Immunology Program, Geriatric Division, Faculty of Medicine, University of Sherbrooke, Sherbrooke, Quebec, Canada. tamas.fulop@usherbrooke.ca
Anis Larbi
Katsuiku Hirokawa
Eugenio Mocchegiani
Bruno Lesourds
Stephen Castle
Anders Wikby
Claudio Franceschi
Graham Pawelec
Université de Sherbrooke · CAHealth and Social Services Centre University Institute of Geriatrics of Sherbrooke · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The primary role of the immune system is to protect the organism against pathogens, but age-associated alterations to immunity increase the susceptibility of the elderly to infectious disease. The exact nature of these changes is still controversial, but the use of screening procedures, such as the SENIEUR protocol to exclude underlying illness, helped to better characterize the changes actually related to physiological aging rather than pathology. It is generally agreed that the most marked changes occur in the cellular immune response reflecting profound alterations in T cells. Much of this is due to thymic involution as well as changes in the proportions of T cell subpopulations resulting from antigen exposure, and altered T cell activation pathways. However, a body of data indicates that innate immune responses, including the critical bridge between innate and adaptive immunity, and antigen presenting capacity are not completely resistant to senescence processes. The consequences of all these alterations are an increased incidence of infections, as well as possibly cancers, autoimmune disorders, and chronic inflammatory diseases. The leading question is what, if anything, can we do to prevent these deleterious changes without dangerously dysregulating the precarious balance of productive immunity versus immunopathology? There are many potential new therapeutic means now available to modulate immunosenescence and many others are expected to be available shortly. One main problem in applying these experimental therapies is ethical: there is a common feeling that as ageing is not a disease; the elderly are not sick and therefore do not require adventurous therapies with unpredictable side-effects in mostly frail individuals. Animal models are not helpful in this context. In this chapter we will first briefly review what we think we know about human immunosenescence and its consequences for the health status of elderly individuals. We will then discuss possible interventions that might one day become applicable in an appropriate ethical environment.

Indexed as

AgingHumansImmune SystemImmunity, InnatePhenotype

Identifiers

PMID18044074
PMCPMC2684090
OpenAlexW1967912375

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.